NEURAXIS, INC. (NRXS) Spending and interest coverage
- R&D / revenue · 12 months: Value 12.14%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 24.21%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -73.67×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 12.14% | Research and development expense / revenue. Period ending 2026-06-30. $645.32K ÷ $5.32M × 100 ≈ 12.14% |
| Stock-based compensation / revenue · 12 months | 24.21% | Share-based compensation / revenue. Period ending 2026-06-30. $1.29M ÷ $5.32M × 100 ≈ 24.21% |
| Interest coverage · 12 months | -73.67× | Operating income ÷ reported interest expense. $-7.68M ÷ $104.28K ≈ -73.67× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 645.32K USD | Research and Development Expense |
| Revenue | 5.32M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 1.29M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -7.68M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 104.28K USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $645.32K | $5.32M | $1.29M | $-7.68M | $104.28K | 12.14% | 24.21% | -73.67× | Reported |
| 2026-03-31 | $475.31K | $4.28M | $820.48K | $-7.28M | $97.92K | 11.10% | 19.16% | -74.30× | Reported |
| 2025-12-31 | $493.61K | $3.57M | $596.85K | $-7.83M | $73.97K | 13.83% | 16.72% | -105.85× | Reported |
| 2025-09-30 | $258.35K | $3.36M | $439.72K | $-7.58M | $-124.36K | 7.68% | 13.08% | (m) | Reported |
| 2025-06-30 | $254.24K | $3.22M | $278.85K | $-7.13M | $-89.35K | 7.90% | 8.67% | (m) | Reported |
| 2025-03-31 | $261.09K | $2.93M | $105.81K | $-7.62M | $-22.09K | 8.90% | 3.61% | (m) | Reported |
| 2024-12-31 | $206.11K | $2.69M | $227.00K | $-7.16M | $174.33K | 7.67% | 8.45% | -41.05× | Reported |
| 2024-09-30 | $130.08K | $2.46M | (m) | $-7.31M | $194.48K | 5.30% | (m) | -37.60× | Reported |
| 2024-06-30 | $102.61K | $2.27M | (m) | $-8.69M | $227.29K | 4.53% | (m) | -38.23× | Reported |
| 2024-03-31 | $158.09K | $2.30M | (m) | $-7.60M | $341.29K | 6.87% | (m) | -22.27× | Reported |
| 2023-12-31 | $169.31K | $2.46M | (m) | $-6.66M | $476.42K | 6.88% | (m) | -13.99× | Reported |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $225.61K | $2.68M | $27.32K | $-3.37M | $318.67K | 8.40% | 1.02% | -10.58× | Reported |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Outset Medical, Inc. (OM) | United States | $0.059B | -1.09 |
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B | |
| QT IMAGING HOLDINGS, INC. (QTI) | United States | $0.037B | |
| EDAP TMS SA (FOCL) | $0.171B | ||
| IRIDEX CORP (IRIX) | United States | $0.011B |